Evidence map›Paper›PMID 31545453›Full record

ArticleOncology reports2019

miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.

Jianjun Huang, Xue Wang, Guobing Wen, Yu Ren

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategies.International journal of clinical oncology · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Insights into the mechanisms of angiogenesis in hepatoblastoma.Frontiers in cell and developmental biology · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jianjun HuangDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China.
Xue WangDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China.
Guobing WenDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China.
Yu RenDepartment of Urologic Surgery, Ningbo Urology and Nephrology Hospital, Ningbo, Zhejiang 315000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are involved in the development of various types of cancers. Dysregulation of miR‑205‑5p has been reported in various types of human cancer. However, little is known concerning the role of miR‑205‑5p in renal cell carcinoma (RCC). The pr~esent study was designed to investigate the role of miR‑205‑5p in RCC. The expression of miR‑205‑5p was measured in clear cell renal cell carcinoma (ccRCC) tissues and cell lines using RT‑qPCR. RCC cell lines were transfected with miR‑205‑5p mimics. CCK‑8 assays, wound healing assays, Matrigel invasion assays and nucleosome ELISAs were used to assess the effects of miR‑205‑5p on cell growth, migration, invasion and apoptosis, respectively. Western blotting was employed to detect changes in protein levels. Bioinformatic analyses and luciferase reporter assays were performed to identify the potential targets of miR‑205‑5p. Mouse xenograft models were used to verify the effect of miR‑205‑5p in vivo. The expression of miR‑205‑5p was found to be downregulated in 25 RCC tissues compared to that noted in the adjacent normal tissues. Decreased expression of miR‑205‑5p was associated with poor clinical outcomes. Based on the results of the in vitro experiments, overexpression of miR‑205‑5p reduced RCC cell proliferation, invasion and migration. Overexpression of miR‑205‑5p also promoted apoptosis and inhibited the EMT in RCC cells. Moreover, the PI3K/Akt signaling pathway was found to be negatively regulated by miR‑205‑5p. Bioinformatic analyses and luciferase reporter assays revealed that miR‑205‑5p directly targeted the 3'‑UTR of vascular endothelial growth factor A (VEGFA). Furthermore, miR‑205‑5p negatively regulated the expression of VEGFA in ccRCC cell lines. In ccRCC tissues, miR‑205‑5p expression was inversely correlated with VEGFA expression. Moreover, overexpression of miR‑205‑5p inhibited RCC growth in vivo in a mouse xenograft model. Overall, miR‑205‑5p functions as a tumor suppressor in RCC by targeting VEGFA and the PI3K/Akt signaling pathway, providing a potential therapeutic target for the treatment of ccRCC.

Indexed as

Signal TransductionAgedAnimalsCarcinoma, Renal CellCell Line, TumorCell MovementCell ProliferationDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiceMicroRNAsMiddle AgedMicroRNAsMIR205, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID31545453
PMCPMC6775807
OpenAlexW2972477728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.